Jardiance vs Trulicity
A side-by-side look at two diabetes medications advertised on TV. Informational only — not medical advice.
| US Jardiance | US Trulicity | |
|---|---|---|
| Generic name | empagliflozin | dulaglutide |
| Drug class | SGLT2 Inhibitor | GLP-1 Receptor Agonist |
| Treats | Type 2 diabetes, heart failure, chronic kidney disease | Type 2 diabetes |
| Category | Diabetes | Diabetes |
| Manufacturer | Boehringer Ingelheim/Eli Lilly | Eli Lilly |
| Year approved | 2014 | 2014 |
| FDA warning | No boxed warning | Black box warning |
| Est. TV ad spend | $280M | $240M |
| Common side effects | Urinary tract infections, Yeast infections, Increased urination, Low blood pressure | Nausea, Diarrhea, Vomiting, Abdominal pain |
Jardiance
Trulicity
Frequently asked questions
Is Jardiance or Trulicity better?
Neither is universally "better." Jardiance (empagliflozin) and Trulicity (dulaglutide) are both used for diabetes, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Jardiance and Trulicity?
Jardiance is a SGLT2 Inhibitor made by Boehringer Ingelheim/Eli Lilly, while Trulicity is a GLP-1 Receptor Agonist made by Eli Lilly. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Jardiance has the larger estimated TV advertising budget of the two.